{"name":"Anhui Shi, MD","slug":"anhui-shi-md","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"atezolizumab or durvalumab","genericName":"atezolizumab or durvalumab","slug":"atezolizumab-or-durvalumab","indication":"Locally advanced or metastatic urothelial carcinoma","status":"phase_3"}]}],"pipeline":[{"name":"atezolizumab or durvalumab","genericName":"atezolizumab or durvalumab","slug":"atezolizumab-or-durvalumab","phase":"phase_3","mechanism":"Atezolizumab and durvalumab are monoclonal antibodies that block the PD-L1 protein, preventing cancer cells from evading the immune system.","indications":["Locally advanced or metastatic urothelial carcinoma","Locally advanced or metastatic non-small cell lung cancer","Locally advanced or metastatic triple-negative breast cancer"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}